BioMoti is pleased to announce that it has signed a Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). This follows our announcement on 31st March 2016 of non-binding Heads of Terms agreement with Physiomics Plc. The acquisition remains conditional on Physiomics Plc completing a successful placing to raise a minimum of £1 million to develop the new joint company’s drug discovery and development pipeline.

For more details, please click to read the Physiomics Plc regulatory update